Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares of Stock

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Urogen Pharma Price Performance

URGN stock opened at $21.14 on Thursday. The stock has a market cap of $989.56 million, a price-to-earnings ratio of -6.11 and a beta of 1.32. The company has a 50 day simple moving average of $21.71 and a 200 day simple moving average of $20.73. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Friday, January 23rd. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.00.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP purchased a new position in shares of Urogen Pharma in the third quarter worth about $84,111,000. Soleus Capital Management L.P. bought a new position in Urogen Pharma in the 2nd quarter worth approximately $29,934,000. SG Americas Securities LLC grew its stake in Urogen Pharma by 19.0% in the 4th quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock valued at $32,264,000 after buying an additional 220,264 shares in the last quarter. TCG Crossover Management LLC bought a new stake in Urogen Pharma during the 3rd quarter valued at $14,311,000. Finally, Orbimed Advisors LLC grew its position in shares of Urogen Pharma by 44.0% in the third quarter. Orbimed Advisors LLC now owns 689,000 shares of the company’s stock valued at $13,746,000 after purchasing an additional 210,600 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.